At the time of writing, Aurinia Pharmaceuticals Inc [AUPH] stock is trading at $8.24, down -0.24%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AUPH shares have gain 6.60% over the last week, with a monthly amount drifted -8.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock has seen the most recent analyst activity on November 04, 2022, when Oppenheimer downgraded its rating to a Perform. On December 10, 2021, upgrade upgraded it’s rating to Outperform and revised its price target to $31 on the stock. Oppenheimer downgraded its rating to a Perform but stick to its price target of $32 on October 28, 2021. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $35 on January 25, 2021. H.C. Wainwright reiterated a Buy rating for this stock on November 03, 2020, and downed its price target to $28. In a note dated June 17, 2020, BTIG Research initiated an Buy rating and provided a target price of $20 on this stock.
For the past year, the stock price of Aurinia Pharmaceuticals Inc fluctuated between $4.71 and $10.67. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $8.24 at the most recent close of the market. An investor can expect a potential return of 57.77% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
According to Aurinia Pharmaceuticals Inc [NASDAQ:AUPH], the company’s sales were 220.36M for trailing twelve months, which represents an 24.32% jump. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.06 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.13 points at the first support level, and at 8.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.44, and for the 2nd resistance point, it is at 8.65.
Ratios To Look Out For
It is important to note that Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] has a current ratio of 5.60. As well, the Quick Ratio is 5.11, while the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 5.35, the price to book ratio is 3.04.
Transactions by insiders
Recent insider trading involved TANG KEVIN, Director, that happened on Dec 09 ’24 when 0.5 million shares were purchased. Director, TANG KEVIN completed a deal on Dec 06 ’24 to buy 0.4 million shares. Meanwhile, Director TANG KEVIN bought 0.3 million shares on Dec 05 ’24.
